Under 10% of people that would benefit from weight-loss injections such as Wegovy have access to them, caution the WHO as it releases its first recommendations on the medications.
Given over a billion individuals worldwide now living with obesity, it is advocating for increased and just availability to this class of drugs.
Per projections, in excess of 2,000,000,000 could be obese by 2030 if no action is taken.
"Our latest guidelines recognises that excess weight is a long-term condition that can be managed with thorough and ongoing care," remarked its chief Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and distribution challenges are major obstacles to broad access to the treatments that can aid individuals in losing considerable body mass, explains the organization.
GLP-1 Therapy Shortage
Even in the current most optimistic outlook, the supply of GLP-1 therapies could only cover approximately 100 million people – less than 10% of the global need, as stated by the WHO.
The advice calls on countries and companies to increase access, by strategies like voluntary licensing.
A patent on a key compound – the core component of the drug Wegovy – is set to lapse in a number of countries in 2026.
The Way Weight-Loss Jabs Function
These medications replicate a biological compound to slow digestion, reduce hunger and boost feelings of fullness so users consume fewer calories.
Individuals usually see weight reduction after several weeks of starting on the once-weekly jabs.
Studies indicates people may see weight return a year later of discontinuing the treatment, as their typical hunger resume.
To be carrying excess weight elevates your risk for experiencing medical conditions, like type 2 diabetes, cardiovascular issues, brain attack, and certain malignancies.
Excess weight impacts individuals in every country and was linked to over three and a half million deaths worldwide in 2024, according to the WHO.
